Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Assets (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Current Assets data on record, last reported at $7.2 million in Q3 2025.

  • For Q3 2025, Current Assets rose 38.64% year-over-year to $7.2 million; the TTM value through Sep 2025 reached $7.2 million, up 38.64%, while the annual FY2024 figure was $4.1 million, 1.53% down from the prior year.
  • Current Assets reached $7.2 million in Q3 2025 per NWBO's latest filing, up from $6.2 million in the prior quarter.
  • Across five years, Current Assets topped out at $17.3 million in Q4 2021 and bottomed at $4.1 million in Q4 2024.
  • Average Current Assets over 5 years is $7.7 million, with a median of $7.2 million recorded in 2022.
  • Peak YoY movement for Current Assets: surged 266.32% in 2021, then tumbled 56.23% in 2023.
  • A 5-year view of Current Assets shows it stood at $17.3 million in 2021, then tumbled by 45.49% to $9.4 million in 2022, then crashed by 56.23% to $4.1 million in 2023, then fell by 1.53% to $4.1 million in 2024, then skyrocketed by 77.2% to $7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $7.2 million in Q3 2025, $6.2 million in Q2 2025, and $4.7 million in Q1 2025.